Jesse Goodman, M.D,
Jesse Goodman brings to Intellia more than three decades of expertise in medicine and public health, including as a professor, practicing clinician and senior government leader. Jesse is currently a professor of medicine at Georgetown University, where he directs the Center on Medical Product Access, Safety and Stewardship (COMPASS). He also is an active clinician, serving as attending physician in infectious diseases.
He was the FDA’s Chief Scientist between 2009 and 2014, and previously served as the FDA’s Deputy Commissioner for Science and Public Health and as Director of the Center for Biologics Evaluation and Research (CBER). Jesse additionally helped develop the FDA’s Regulatory Science and Medical Countermeasures Initiatives and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. As the FDA’s Chief Scientist, he led preparations and responses to major public health threats, including emerging infectious diseases, disasters and terrorism, such as West Nile Virus and the 2009 H1N1 influenza pandemic. Previously, he was professor and chief of infectious diseases at the University of Minnesota, where his laboratory first isolated and characterized the biology of the emerging tick-borne pathogen Anaplasma phagocytophilum and where he also lead clinical trials helping to develop new anti-infective agents.
Jesse serves as an independent non-executive director for GlaxoSmithKline plc, a global pharmaceutical company; as president and trustee of the U.S. Pharmacopeial Convention; and on the Regulatory Working Group of the Coalition on Epidemic Preparedness Innovation (CEPI). Jesse graduated with an AB in biology from Harvard University; earned a master’s in public health from the University of Minnesota; and received his M.D. from the Albert Einstein College of Medicine. He completed his residency and fellowship training at the Hospital of the University of Pennsylvania and at the University of California at Los Angeles, where he was also chief medical resident. He is board-certified in internal medicine, infectious diseases and oncology and has been elected to the American Society for Clinical Investigation and to the U.S. National Academy of Medicine.